T. Rowe Price Associates’s Janux Therapeutics JANX Stock Holding History

T. Rowe Price Associates’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	84,981 +26,181	+45%	+$379K	﹤0.01%	2201
2026 Q1	$818K	Sell	58,800 -685,666	-92%	-$9.4M	﹤0.01%	2241
2025 Q4	$10.3M	Sell	744,466 -521,090	-41%	-$12.3M	﹤0.01%	1230
2025 Q3	$30.9M	Sell	1,265,556 -527,871	-29%	-$12.9M	﹤0.01%	944
2025 Q2	$41.4M	Buy	1,793,427 +400,601	+29%	+$10.6M	﹤0.01%	775
2025 Q1	$37.6M	Buy	1,392,826 +282,848	+25%	+$10.7M	﹤0.01%	805
2024 Q4	$59.4M	Buy	1,109,978 +950,557	+596%	+$50.3M	0.01%	702
2024 Q3	$7.24M	Sell	159,421 -92,937	-37%	-$4.04M	﹤0.01%	1203
2024 Q2	$10.6M	Buy	252,358 +232,762	+1,188%	+$10.9M	﹤0.01%	1103
2024 Q1	$739K	Buy	+19,596	New	+$427K	﹤0.01%	2040

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

T. Rowe Price Associates's JANX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Janux Therapeutics (JANX) stake by 45% in Q2 2026, buying an estimated $379K and bringing the position to 84,981 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

T. Rowe Price Associates first reported a position in JANX in Q1 2024 and has held it in 10 quarters since. The position peaked at $59.4M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

T. Rowe Price Associates held 84,981 shares of Janux Therapeutics worth $1.31M as of Q2 2026.
T. Rowe Price Associates bought 26,181 Janux Therapeutics shares in Q2 2026, an estimated $379K.
Janux Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2201 holding.
T. Rowe Price Associates first reported a position in Janux Therapeutics in Q1 2024 and has held it in 10 quarters since.
T. Rowe Price Associates's Janux Therapeutics position peaked at $59.4M in Q4 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.